Aura Biosciences, Inc. (AURA)
Aura Biosciences, Inc. (AURA)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -33,685 | -25,559 | -26,130 | -54,502 |
| Depreciation expense | 274 | 272 | 280 | 577 |
| Accretion income on marketable securities | 292 | 424 | 337 | 785 |
| Stock-based compensation expense | 3,824 | 3,282 | 3,688 | 7,347 |
| Other non-cash items | 0 | 0 | 0 | 27 |
| Non-cash lease expense | 412 | 402 | 392 | 757 |
| Prepaid expenses and other assets | -1,727 | -2,683 | 1,534 | -2,882 |
| Other long-term assets | 46 | 194 | 92 | -333 |
| Accounts payable | 1,024 | -430 | 602 | -1,018 |
| Accrued expenses and other liabilities | -2,745 | -124 | 3,345 | 910 |
| Operating lease liabilities | -386 | -377 | -358 | -657 |
| Net cash used in operating activities | -29,893 | -20,469 | -20,144 | -44,129 |
| Purchases of property and equipment | 102 | 176 | 45 | 226 |
| Purchases of marketable securities | NaN | 0 | 73,974 | 9,984 |
| Proceeds from sale of marketable securities | NaN | NaN | NaN | 0 |
| Maturities of marketable securities | 55,000 | 30,000 | 30,000 | 60,000 |
| Net cash provided by investing activities | 54,898 | 29,824 | -44,019 | 49,790 |
| Proceeds from exercise of stock options | 56 | 0 | 1,008 | 2 |
| Proceeds from issuance of common stock from follow-on offering, net of issuance costs | NaN | 0 | 0 | 46,517 |
| Proceeds from issuance of pre-funded warrants from follow-on offering, net of issuance costs | NaN | 0 | 0 | 14,156 |
| Proceeds from issuance of common stock warrants from follow-on offering, net of issuance costs | NaN | 0 | 0 | 9,254 |
| Proceeds from issuance of common stock under atm facility, net of issuance costs | NaN | 2,767 | 3,287 | NaN |
| Proceeds from exercise of warrants | 123 | NaN | NaN | NaN |
| Proceeds from espp purchases | 121 | 0 | 68 | 96 |
| Net cash provided by financing activities | 300 | 2,767 | 4,363 | 70,025 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 25,305 | 12,122 | -59,800 | 75,686 |
| Effect of exchange rate changes on cash and cash equivalents | -27 | -160 | -26 | NaN |
| Cash, cash equivalents and restricted cash at beginning of period | 60,283 | 48,321 | 32,461 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 85,561 | 60,283 | 48,321 | NaN |